Annovis Bio Inc. (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer’s pathology. Annovis noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson’s and Alzheimer’s disease biology.
The announcement is significant because it addresses a critical unmet need in Parkinson’s disease: cognitive decline, which affects many patients and currently lacks effective treatments. The identification of a subgroup with amyloid co-pathology, who showed the most pronounced benefits, suggests that buntanetap could be particularly valuable for patients with mixed pathology, a common but often overlooked condition. The biomarker reductions also provide mechanistic evidence that the drug is engaging its target, offering a biological basis for the cognitive improvements seen in the trial.
For investors, these results could expand the potential market for buntanetap beyond Parkinson’s to include Alzheimer’s disease and other neurodegenerative conditions. Annovis is developing the drug as a broad-spectrum therapy that inhibits multiple neurotoxic proteins, including amyloid-beta, tau, and alpha-synuclein, which are implicated in various dementias. The company’s focus on overlapping pathologies aligns with a growing consensus in the field that effective treatments must address multiple disease mechanisms.
The full press release is available at https://ibn.fm/CK0zo. Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
The implications of this announcement are far-reaching. If confirmed in larger trials, buntanetap could become the first treatment to reverse cognitive decline in Parkinson’s disease, a condition where current therapies only manage motor symptoms. The biomarker data also suggest that the drug may have disease-modifying potential, which could slow or halt progression. For the broader neurodegenerative disease field, these results support the hypothesis that targeting multiple toxic proteins is a viable therapeutic strategy, potentially paving the way for combination therapies or multi-target drugs.
